Novocure Ltd Stock
€14.38
Your prediction
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | -1.370% | -15.709% | -8.320% | -32.425% | -50.618% | -80.688% | -76.153% |
Ironwood Pharmaceuticals | -7.170% | -0.935% | -34.161% | -91.092% | -87.381% | -94.877% | -94.045% |
Arrowhead Pharmaceuticals Inc. | 2.400% | -2.968% | 12.868% | -38.049% | -22.222% | -55.650% | -52.312% |
Iovance Biotherapeutics Inc. | 8.320% | -1.097% | -49.186% | -79.453% | -77.275% | -78.554% | -94.360% |
News

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society

Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
-
PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31

Novocure Reports First Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive